mTOR 信号通路：从分子到临床方面

人体基因检测需要多少钱—比较

开会学习《肿瘤靶向药物选择的基因突变标准》《Int J Mol Sci》在. 2022 Sep 4;23(17):10132.发表了一篇题目为《靶向胰腺癌中的 PI3K/AKT/mTOR 信号通路：从分子到临床方面》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Silviu Stanciu, Florentina Ionita-Radu, Constantin Stefani, Daniela Miricescu, Iulia-Ioana Stanescu-Spinu, Maria Greabu, Alexandra Ripszky Totan, Mariana Jinga 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

PI3K/AKT/mTOR,抑制剂,胰腺癌,风险因素,肿瘤微环境

肿瘤靶向治疗基因检测临床应用结果

尽管胰腺癌（PC）由于其发病率低而在过去被认为是一种孤儿癌，但它可能在未来成为癌症死亡的主要原因之一。胰腺导管腺癌 (PDAC) 是最常见的 PC 类型，是一种高度侵袭性的恶性肿瘤，5 年生存率低于 10%。不可改变的（家族史、年龄、遗传易感性）和可改变的（吸烟、酒精、急性和慢性胰腺炎、糖尿病、肠道微生物群）危险因素与 PC 发病机制有关。由各种因素引起的慢性炎症在 PC 从起始到转移的发展中起着至关重要的作用。在 PC 等多种恶性疾病中，细胞因子、趋化因子和生长因子激活 I 类磷酸肌醇 3 激酶 (PI3K)/蛋白激酶 B (AKT)/雷帕霉素哺乳动物靶标 (mTOR) (PI3K/AKT/mTOR) 信号通路，在细胞生长、存活、增殖、新陈代谢和运动中起关键作用。目前，mTOR、AKT 和 PI3K 抑制剂用于临床研究。此外，PI3K/mTOR 双抑制剂正在体外和体内进行测试，对 PC 患者有希望的结果。本综述的主要目的是介绍临床、体内和体外研究中使用的 PC 发病率、危险因素、肿瘤微环境发展以及 PI3K/AKT/mTOR 失调和抑制剂。抑制剂；胰腺癌;风险因素;肿瘤微环境。

肿瘤发生与复发转移国际数据库描述：

Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to its low incidence, it may become in the future one of the leading causes of cancer death. Pancreatic ductal adenocarcinoma (PDAC) is the most frequent type of PC, being a highly aggressive malignancy and having a 5-year survival rate of less than 10%. Non-modifiable (family history, age, genetic susceptibility) and modifiable (smoking, alcohol, acute and chronic pancreatitis, diabetes mellitus, intestinal microbiota) risk factors are involved in PC pathogenesis. Chronic inflammation induced by various factors plays crucial roles in PC development from initiation to metastasis. In multiple malignant conditions such as PC, cytokines, chemokines, and growth factors activate the class I phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) signaling pathway, which plays key roles in cell growth, survival, proliferation, metabolism, and motility. Currently, mTOR, AKT, and PI3K inhibitors are used in clinical studies. Moreover, PI3K/mTOR dual inhibitors are being tested in vitro and in vivo with promising results for PC patients. The main aim of this review is to present PC incidence, risk factors, tumor microenvironment development, and PI3K/AKT/mTOR dysregulation and inhibitors used in clinical, in vivo, and in vitro studies.Keywords: PI3K/AKT/mTOR; inhibitors; pancreatic cancer; risk factors; tumor microenvironment.

(责任编辑：佳学基因)